The FDA has approved Wyeth’s Xyntha (recombinant antihemophilic factor VIII) for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A. Xyntha is plasma/albumin-free and is not derived from animal or human sources. Xyntha is expected to be available in September 2008.

For more information call (800) 934-5556 or visit